ValoreQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMSpese di vendita, generali e amministrative2.86 B2.55 B2.65 B2.63 B2.9 B2.7 B10.88 BRicerca e sviluppo4.58 B3.62 B4.05 B4.23 B3.89 B12.59 B24.76 BReddito operativo1.64 B5.87 B4.99 B6.51 B375 M-3.4 B8.48 BProventi non operativi, Totale123 M202 M150 M430 M-298 M-7 M275 MOneri finanziari, al netto degli interessi capitalizzati328 M313 M305 M327 M412 M479 M1.52 BProventi non operativi, esclusi gli oneri finanziari-76 M-146 M-162 M-135 M-279 M-348 M-924 MEntrate/uscite straordinarie-129 M35 M7 M238 M-431 M-138 M-324 MUtile al lordo delle imposte4.17 B5.9 B5 B6.75 B3.42 B-3.53 B11.63 BQuota di utile———————Imposte426 M818 M571 M958 M457 M709 M2.69 BInteressi di minoranza1 M6 M1 M2 M0-3 M0Altri proventi/oneri al netto delle imposte101 M-109 M-335 M51 M-118 M-20 M-422 MUtile netto al lordo delle attività cessate3.74 B5.08 B4.43 B5.79 B2.96 B-4.24 B8.94 BAttività cessate———————Utile netto3.74 B5.08 B4.43 B5.79 B2.96 B-4.24 B8.94 BRegolazione della diluizione———————Dividendi privilegiati———————Utile netto diluito attribuibile agli azionisti ordinari3.74 B5.08 B4.43 B5.79 B2.96 B-4.24 B8.94 BUtile base per azione (EPS base)1.482.011.762.321.21-1.723.57Utile diluito per azione (EPS diluito)1.492.011.762.321.19-1.723.55Numero medio di azioni ordinarie in circolazione2.53 B2.52 B2.51 B2.5 B2.5 B2.47 B—Azioni diluite in circolazione2.54 B2.53 B2.51 B2.5 B2.51 B2.47 B—EBITDA2.84 B6.97 B6.11 B7.66 B2.84 B-1.88 B14.73 BEBIT1.64 B5.87 B4.99 B6.51 B375 M-3.4 B8.48 BCosto del fatturato3.83 B3.42 B3.56 B3.85 B5.55 B4.2 B17.16 BAltri costi del venduto———————Ammortamento e svalutazione (liquidità)1.2 B1.1 B1.12 B1.15 B2.47 B1.51 B6.25 B
Merck & Company, Inc. Common Stock
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fifth on the list of largest biomedical companies by revenue.
The company's revenues are primarily from cancer treatments, vaccines, and animal health products. In 2024, 46% of the company's revenue, or $29.5 billion, came from sales of Keytruda, a PD-1 inhibitor used to treat various types of cancers, and 13% of the company's revenue, or $8.6 billion, came from sales of Gardasil, an HPV vaccine. In addition, 9% of the company's revenue, or $5.8 billion, came from the sales of animal health products.
The company is ranked 65th on the Fortune 500 and 76th on the Forbes Global 2000.
In 1891, Merck & Co. was established as the American affiliate of the Merck Group, founded by the Merck family, and the companies are still in trademark disputes in several countries over the right to use the name "Merck".